Prostate Cancer: Metastatic Late Stage

About the Oncotype DX AR-V7 Nucleus Detect test

Why Would Your Doctor Order the Oncotype DX AR-V7 Nucleus Detect Test?


This webinar explains what metastatic castration-resistant prostate cancer (mCRPC) is and how it is currently treated. In addition it will explain the role of resistance to androgen receptor-targeted drugs like Xtandi and Zytiga and its impact on treating mCRPC.

If you’ve been diagnosed with metastatic castration-resistant prostate cancer (mCRPC), the Oncotype DX AR-V7 Nucleus Detect test can help you and your doctor understand what therapy is right for you.

The AR-V7 Nucleus Detect test identifies whether your tumor will respond to androgen receptor (AR)-targeted therapies—such as XTANDI® or ZYTIGA®—or whether you should consider chemotherapy or other therapies.*

1 in 3 patients are resistant to AR-targeted therapies after two rounds of treatment.

The right treatment, at the right time

Although AR-targeted therapies are a breakthrough in mCRPC treatment, most mCRPC patients acquire resistance to them over time. In fact, resistance becomes more likely with each round of AR-targeted treatments. Once a patient’s tumor is resistant, AR-targeted treatments stop providing benefits and studies show patients are substantially more likely to live longer when treated with chemotherapy.

The AR-V7 Nucleus Detect test accurately pinpoints resistance to AR-targeted therapies, helping you get the right treatment at the right time. Your test results will provide you and your doctor with critical information you need to decide when to transition from AR-targeted therapies to chemotherapy or other therapies.

How it works

The AR-V7 Nucleus Detect test only requires a simple blood draw at your doctor’s office or nearby lab. About two weeks after Genomic Health receives your blood draw, your test results will be available to your doctor.

The results will say your tumor is either AR-V7 positive (AR-V7+) or AR-V7 negative (AR-V7-). An AR-V7+ result means your tumor will not respond to AR-targeted therapies and you should consider other treatments instead. Learn more about what to expect .

*Xtandi® is a registered trademark of Astellas Pharma, Inc. Zytiga® is a registered trademark of Johnson and Johnson.

Get Our Patient Brochure


Finding the most effective treatment for your patients with metastatic castration-resistant prostate cancer (mCRPC) can be a challenge. The Oncotype DX AR-V7 Nucleus Detect test helps you quickly and confidently determine the next step.

Stay in Touch

Have a specific question? Want to keep up with our latest news? We're here for you.

Contact Us
Making cancer care smarter.™